Rapid Detector Funded

Of all the threat scenarios facing emergency responders around the country, the release and spread of a dangerous biotoxin in a large public space is one of the most troubling.

The reason is simple: Though early diagnosis of biotoxin exposure is important for consequence mitigation and the key to saving lives, no current method exists for the quick, efficient detection of such poisonous agents.

That could all change soon, as researchers at Sandia National Laboratories in California have secured funding from the National Institute of Allergy and Infectious Diseases (NIAID) to design and engineer a small, portable microfluidic device that will offer rapid detection of biotoxin exposure in humans. In addition to speed, the device promises to offer high sensitivity, the capability to detect both presymptomatic and symptomatic markers, and ease-of-use, Sandia said in a statement.

The NIAID, part of the National Institutes of Health (NIH), has committed $3.2 million to the five-year project.

Sandia biochemist Dan Throckmorton prepares to add a sample to the prototype diagnostic device. After he adds the sample, computer-controlled electronics direct a series of sample analysis steps. Laser-induced fluorescence is used for highly sensitive detection of assay products. The final diagnostic device will feature a miniaturized, portable fluorescence detector. (Photo: Dino Vournas)

The effort is being undertaken in collaboration with B.R. Singh, a professor at the University of Massachusetts at Dartmouth and Steve Binder at Bio-Rad Laboratories. Sandia is a National Nuclear Security Administration (NNSA) laboratory.

Instead of sending those suspected of being infected with a biotoxin -- spectators at a sporting event who have been contaminated by a terrorist release, for example -- to a medical facility where lab results could take days or weeks, Sandia’s Anup Singh said a lightweight, portable device would allow on-site emergency personnel to draw blood samples and make a rapid determination as to the degree of exposure. Those in need of treatment can then be monitored, and countermeasures can be immediately executed at the facility to mitigate further damage.

“It could be a fireman, a paramedic or simply a primary care practitioner who might use this device one day,” said Singh, a chemical engineer at Sandia who will serve as the project’s principal investigator. The only stipulation, he said, is that the device’s end user will need to be authorized and trained in drawing blood, though that could change eventually. “In the not-so-distant future, a more accessible and readily available specimen such as saliva might be able to diagnose toxins,” he said.

Currently, said Singh, the technology to quickly test individuals for biotoxin exposure does not exist. Those suspected of being intoxicated must give blood samples at a medical facility and wait for laboratory analysis.

Singh said those toxins able to be detected by the device will include botulinum toxin, SEB (Staphylococcal enterotoxin B), shiga toxins, Clostridium perfringens epsilon toxin, and others.

The Sandia-led project -- which will include collaborations with the University of Massachusetts and Bio-Rad Laboratories -- builds on the success of the lab’s well-known “spit project,” a program also funded by the NIH. That project could allow dentists to quickly test patients for gum disease and other afflictions via saliva samples.

Anson Hatch, a Sandia bioengineer and a microfluidic expert, will lead the microfluidic assay development effort. The system will incorporate microfluidic methods developed by Hatch and others at Sandia that facilitate hands-free analysis by integrating sample pretreatment with electrophoretic immunoassays that quickly measure analyte concentrations in blood. The self-contained device will consist of miniaturized electronics, optical elements, fluid-handling components, data acquisition software and a user interface.

The technology, device and methods, said Singh, can also be extended to detection of biomarkers of other systemic diseases and conditions such as cancer and cardiovascular disease.

For more information, visit: sandia.gov